Porphyria cutanea tarda (PCT) is a metabolic disorder characterized by a reduced hepatic activity of uroporphynogen decarboxylase (URO-D), an enzyme of the heme synthesis. The clinical features of PCT may be brought into light by hepatic injury induced by hepatitis C virus (HCV). A significant association between HCV and PCT is well recognized, although the role of HCV in the appearance of PCT is still debated because confounding factors often coexist, such as alcohol, other viruses, drugs or iron overload (). HCV therapy may improve PCT although PCT was rarely reported as a de novo occurrence during an interferon/ribavirin therapy (Jessner et al. Hepatology 2002;36:1301-1302); here, we describe two such other cases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2004.10.029DOI Listing

Publication Analysis

Top Keywords

porphyria cutanea
8
cutanea tarda
8
pct
6
occurrence porphyria
4
tarda peginterferon/ribavirin
4
peginterferon/ribavirin therapy
4
therapy chronic
4
chronic viral
4
viral hepatitis
4
hepatitis porphyria
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!